Showing 3 posts of 3 posts found.


Europe approves first treatment for transthyretin amyloidosis in cardiomyopathy patients: Pfizer’s Vyndaqel

February 19, 2020
Research and Development, Sales and Marketing Europe, Pfizer, Vyndaqel, pharma, transthyretin amyloidosis

The European Commission (EC) has awarded marketing approval to Pfizer’s Vyndaqel (tafamidis), it has emerged, for the treatment of wild-type …

Pfizer’s Vyndaqel scores CHMP support for transthyretin amyloidosis in cardiomyopathy patients

December 16, 2019
Sales and Marketing Pfizer, Vyndaqel, pharma

Pfizer’s once-daily 61mg oral capsule formulation of Vyndaqel (tafamidis) has secured a positive opinion from the European Medicines Agency’s (EMA) …

FDA approves first two drugs for transthyretin amyloid cardiomyopathy

May 7, 2019
Manufacturing and Production, Sales and Marketing FDA, Pfizer, US, Vyndamax, Vyndaqel, pharma

The FDA has approved its first two therapies for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), …

Latest content